Bladder Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are receiving treatment with PADCEV Injection as directed by its officially approved local prescribing guidelines.
Who may not be able to join:
- People for whom PADCEV Injection is considered medically unsuitable or unsafe according to the officially approved local prescribing guidelines.
- People who are receiving, or are planned to receive, any other experimental or investigational medicine during the period of observation in this trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Central Contact, Astellas Pharma Korea, Inc.
Phone: 800-888-7704
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of patients with an Adverse Event; Number of patients with an adverse drug reaction (ADR); Number of patients with a serious AE (SAE); Number of patients with a serious ADR (SADR); Number of patients with an unexpected AE (UAE); Number of patients with an unexpected ADR (UADR); Number of patients with an important risk
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.